SNTI vs. TVGN, PMCB, APTO, AIM, COEP, ZIVO, ONVO, CHRO, BCDA, and GENE
Should you be buying Senti Biosciences stock or one of its competitors? The main competitors of Senti Biosciences include Tevogen Bio (TVGN), PharmaCyte Biotech (PMCB), Aptose Biosciences (APTO), AIM ImmunoTech (AIM), Coeptis Therapeutics (COEP), ZIVO Bioscience (ZIVO), Organovo (ONVO), Chromocell Therapeutics (CHRO), BioCardia (BCDA), and Genetic Technologies (GENE). These companies are all part of the "biological products, except diagnostic" industry.
Senti Biosciences (NASDAQ:SNTI) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and community ranking.
Senti Biosciences received 3 more outperform votes than Tevogen Bio when rated by MarketBeat users.
In the previous week, Senti Biosciences had 1 more articles in the media than Tevogen Bio. MarketBeat recorded 1 mentions for Senti Biosciences and 0 mentions for Tevogen Bio. Senti Biosciences' average media sentiment score of 0.00 equaled Tevogen Bio'saverage media sentiment score.
25.7% of Senti Biosciences shares are owned by institutional investors. 12.5% of Senti Biosciences shares are owned by company insiders. Comparatively, 56.6% of Tevogen Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Senti Biosciences presently has a consensus target price of $6.00, suggesting a potential upside of 1,402.25%. Given Senti Biosciences' higher possible upside, equities analysts clearly believe Senti Biosciences is more favorable than Tevogen Bio.
Tevogen Bio has lower revenue, but higher earnings than Senti Biosciences.
Senti Biosciences has a beta of 2.88, indicating that its share price is 188% more volatile than the S&P 500. Comparatively, Tevogen Bio has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500.
Tevogen Bio has a net margin of 0.00% compared to Senti Biosciences' net margin of -2,692.82%. Tevogen Bio's return on equity of -21.83% beat Senti Biosciences' return on equity.
Summary
Senti Biosciences beats Tevogen Bio on 7 of the 12 factors compared between the two stocks.
Get Senti Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Senti Biosciences Competitors List
Related Companies and Tools
